GRDN Guardian Pharmacy Services, Inc.
Retail-Drug Stores and Proprietary Stores · NYSE · SEC CIK 1802255 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY4.9%
TTM net income YoY85.8%
TTM EPS YoY84.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin22.4%
Operating margin6.5%
Net margin5.1%
FCF margin—
EBITDA margin8.1%
Returns
ROE33.2%
ROA17.0%
ROIC (approx.)46.2%
Asset turnover3.30x
Leverage & solvency
Liabilities / assets43.1%
Debt / equity0.00x
Current ratio1.65x
Interest coverage145.28x
Cash quality & payout
Operating cash flow / net income1.53x
Accruals ratio-8.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $1.45B | $1.23B |
| Cost of revenue | $1.16B | $984.04M |
| Gross profit | $292.72M | $244.37M |
| SG&A expense | $220.02M | $307.29M |
| Operating income | $72.70M | -$62.92M |
| Interest expense | $665,000 | $3.28M |
| Pretax income | $73.42M | -$66.48M |
| Income tax | $24.46M | $4.56M |
| Net income | $49.22M | -$110.05M |
| EBITDA | $95.04M | -$43.15M |
| EPS (diluted) | — | — |
| Balance sheet | ||
| Cash & equivalents | $65.62M | $4.66M |
| Receivables | $101.61M | $97.15M |
| Inventory | $43.36M | $40.55M |
| Current assets | $221.63M | $151.99M |
| PP&E, net | $55.52M | $49.88M |
| Goodwill | $79.74M | $69.30M |
| Intangibles | $18.48M | $14.91M |
| Total assets | $412.66M | $320.81M |
| Current liabilities | $160.70M | $144.12M |
| Long-term debt | $0 | $0 |
| Total debt | $0 | $0 |
| Total liabilities | $194.73M | $170.83M |
| Shareholders' equity | $205.76M | $142.67M |
| Net debt | -$65.62M | -$4.66M |
| Cash flow statement | ||
| Operating cash flow | $100.25M | $57.96M |
| Capital expenditure | $13.42M | $14.71M |
| Free cash flow | $86.84M | $43.25M |
| Investing cash flow | -$32.23M | -$30.41M |
| Financing cash flow | -$7.07M | -$23.64M |
| Depreciation & amortization | $22.34M | $19.77M |
| Stock-based compensation | $13.85M | $131.49M |
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.